| treatment |
|
comparator |
All cause death | stroke (fatal and non fatal) | myocardial infarction (fatal and non fatal) | microvascular events | macrovascular or microvascular events | Peripheral vascular events | Diabetes-related death | Any diabetes-related outcomes |
|
|
| Glimepiride | diabetes type 2, in all type of patients | vs metformin | - | - | - | - | - | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| All cause death | no data | | stroke (fatal and non fatal) | no data | | myocardial infarction (fatal and non fatal) | no data | | microvascular events | no data | | macrovascular or microvascular events | no data | | Peripheral vascular events | no data | | Diabetes-related death | no data | | Any diabetes-related outcomes | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Charpentier, 2001 | glimepiride monotherapy | metformin monotherapy | Type 2 diabetic patients aged 35-70 years inadequately controlled by metformin monotherapy 2550 mg daily for at least 4 weeks |
|
| Gliclazide | diabetes type 2, in all type of patients | vs nateglinide (add on MET) | - | - | - | - | - | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| All cause death | no data | | stroke (fatal and non fatal) | no data | | myocardial infarction (fatal and non fatal) | no data | | microvascular events | no data | | macrovascular or microvascular events | no data | | Peripheral vascular events | no data | | Diabetes-related death | no data | | Any diabetes-related outcomes | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Ristic, 2006 | gliclazide plus metformin | nateglinide plus metformin | |
|
| Gliclazide | diabetes type 2, in all type of patients | vs pioglitazone (add on MET) | - | - | - | - | - | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| All cause death | no data | | stroke (fatal and non fatal) | no data | | myocardial infarction (fatal and non fatal) | no data | | microvascular events | no data | | macrovascular or microvascular events | no data | | Peripheral vascular events | no data | | Diabetes-related death | no data | | Any diabetes-related outcomes | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Matthews, 2005 | gliclazide 80 mg o.d. (titrated up to 320 mg | pioglitazone 15 mg o.d. (titrated up to 45 mg | Patients with poorly controlled type 2 diabetes |
|
| Gliclazide | diabetes type 2, in all type of patients | vs rosiglitazone (add on MET) | - | - | - | - | - | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| All cause death | no data | | stroke (fatal and non fatal) | no data | | myocardial infarction (fatal and non fatal) | no data | | microvascular events | no data | | macrovascular or microvascular events | no data | | Peripheral vascular events | no data | | Diabetes-related death | no data | | Any diabetes-related outcomes | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Khanolkar, 2008 | metformin and gliclazide | metformin and rosiglitazone | |
|
| Glimeripide | diabetes type 2, in all type of patients | vs placebo (add on MET) | - | - | - | - | - | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| All cause death | no data | | stroke (fatal and non fatal) | no data | | myocardial infarction (fatal and non fatal) | no data | | microvascular events | no data | | macrovascular or microvascular events | no data | | Peripheral vascular events | no data | | Diabetes-related death | no data | | Any diabetes-related outcomes | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| LEAD-2 (Nauck) Sulf vs pbo, 2009 | glimepiride (4 mg once daily). | placebo | subjects previously treated with oral antidiabetes (OAD) therapy | | Charpentier, 2001 | metformin and glimepiride | metformin | Type 2 diabetic patients aged 35-70 years inadequately controlled by metformin monotherapy 2550 mg daily |
|
| Glimeripide | diabetes type 2, in all type of patients | vs placebo | - | - | - | - | - | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| All cause death | no data | | stroke (fatal and non fatal) | no data | | myocardial infarction (fatal and non fatal) | no data | | microvascular events | no data | | macrovascular or microvascular events | no data | | Peripheral vascular events | no data | | Diabetes-related death | no data | | Any diabetes-related outcomes | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Study 201 (Goldberg), 1996 | glimepiride, 1, 4, or 8 mg once daily | placebo | patients with NIDDM | | Schade, 1998 | glimepiride at individually determined optimal dose (1-8 mg of glimepiride) for 10+12 weeks | placebo | patients with type 2 diabetes mellitus for whom diet therapy is unsuccessful | | Rosenstock, 1996 | glimepiride 8 mg q.d., 4 mg b.i.d., 16 mg q.d., or 8 mg b.i.d | placebo | previously treated NIDDM patients | | Luis Bautista, 2003 | glimepiride with titration to 2 mg and 4 mg for FPG levels >120 mg/dL | placebo | Mexican American Patients with type 2 diabetes mellitus | | Kaneko, 1993 | glimepiride 0.25mg od, 0.5mg od | placebo | | | Study 202, | glimepiride 1-8mg od | placebo | |
|
| Glimeripide | diabetes type 2, in all type of patients | vs placebo (add on insulin) | - | - | - | - | - | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| All cause death | no data | | stroke (fatal and non fatal) | no data | | myocardial infarction (fatal and non fatal) | no data | | microvascular events | no data | | macrovascular or microvascular events | no data | | Peripheral vascular events | no data | | Diabetes-related death | no data | | Any diabetes-related outcomes | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Riddle, 1994 | Glimepiride (16 mg/day) plus insulin | insulin
plus placebo | obese
patients with type 2 diabetes insufficiently controlled
by full dosages of sulphonylureas (glimepiride titrated up to 8mg twice daily and with laboratory-monitored FPG of 10 to 16
mmol/L (180 to 300 mg/dl)) |
|
| Glimeripide | diabetes type 2, in all type of patients | vs gliclazide | - | - | - | - | - | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| All cause death | no data | | stroke (fatal and non fatal) | no data | | myocardial infarction (fatal and non fatal) | no data | | microvascular events | no data | | macrovascular or microvascular events | no data | | Peripheral vascular events | no data | | Diabetes-related death | no data | | Any diabetes-related outcomes | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Charpentier (301F), | glimepiride 1-4mg od | gliclazide 80-320 mg/day (od or bid) | |
|
| Glimeripide | diabetes type 2, in all type of patients | vs glibenclamide | - | - | - | - | - | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| All cause death | no data | | stroke (fatal and non fatal) | no data | | myocardial infarction (fatal and non fatal) | no data | | microvascular events | no data | | macrovascular or microvascular events | no data | | Peripheral vascular events | no data | | Diabetes-related death | no data | | Any diabetes-related outcomes | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Draeger, 1996 | glimepiride 1 mg daily | 2.5 mg glibenclamide | type 2 diabetic patients stabilised on glibenclamide | | Protocol 311, | glimepiride 1-8mg od | glibenclamide 1.75-14 mg/day
(od or bid) | |
|
| Glimeripide | diabetes type 2, in all type of patients | vs gliclazide or glibenclamide | - | - | - | - | - | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| All cause death | no data | | stroke (fatal and non fatal) | no data | | myocardial infarction (fatal and non fatal) | no data | | microvascular events | no data | | macrovascular or microvascular events | no data | | Peripheral vascular events | no data | | Diabetes-related death | no data | | Any diabetes-related outcomes | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Inukai, 2005 | glimepiride | gliclazide or glibenclamide | Japanese type 2 diabetic patients (HbA1C > or = 7.0%), maintained on a conventional SU |
|
| Glimeripide | diabetes type 2, in all type of patients | vs glimepiride bid | - | - | - | - | - | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| All cause death | no data | | stroke (fatal and non fatal) | no data | | myocardial infarction (fatal and non fatal) | no data | | microvascular events | no data | | macrovascular or microvascular events | no data | | Peripheral vascular events | no data | | Diabetes-related death | no data | | Any diabetes-related outcomes | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Sonnenberg, 1997 | glimepirid e6mg od | glimepiride 3mg bid | |
|
| Glimeripide | diabetes type 2, in all type of patients | vs glipizide | - | - | - | - | - | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| All cause death | no data | | stroke (fatal and non fatal) | no data | | myocardial infarction (fatal and non fatal) | no data | | microvascular events | no data | | macrovascular or microvascular events | no data | | Peripheral vascular events | no data | | Diabetes-related death | no data | | Any diabetes-related outcomes | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Clark (301), 1997 | glimepiride 1-16 mg/day (od or bid) | glipizide 2.5-40 mg/day (od or bid) | |
|
| Glimeripide | diabetes type 2, in all type of patients | vs glyburide | - | - | - | - | - | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| All cause death | no data | | stroke (fatal and non fatal) | no data | | myocardial infarction (fatal and non fatal) | no data | | microvascular events | no data | | macrovascular or microvascular events | no data | | Peripheral vascular events | no data | | Diabetes-related death | no data | | Any diabetes-related outcomes | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Dills, 1996 | glimepiride 1-16mg od | non-micronized glyburide 1.25-20mg od | patients with non-insulin dependent diabetes |
|
| Glipizide | diabetes type 2, in all type of patients | vs control (add on MET) | - | - | - | - | - | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| All cause death | no data | | stroke (fatal and non fatal) | no data | | myocardial infarction (fatal and non fatal) | no data | | microvascular events | no data | | macrovascular or microvascular events | no data | | Peripheral vascular events | no data | | Diabetes-related death | no data | | Any diabetes-related outcomes | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Goldstein, | glipizide/metformin 5/500 mg tablets | metformin 500-mg | patients with type 2 DM that is uncontrolled by at least half the maximum labeled daily dose of a sulfonylurea |
|
| Glipizide | diabetes type 2, in all type of patients | vs glyburide | - | - | - | - | - | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| All cause death | no data | | stroke (fatal and non fatal) | no data | | myocardial infarction (fatal and non fatal) | no data | | microvascular events | no data | | macrovascular or microvascular events | no data | | Peripheral vascular events | no data | | Diabetes-related death | no data | | Any diabetes-related outcomes | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Rosenstock, 1993 | glipizide, 2.5 or 5 mg/day | glyburide, 1.25 or 2.5 mg/day | elderly patients with NIDDM that was controlled for at least 3 months with oral sulfonylurea therapy | | Birkeland, 1994 | glipizide | glyburide | NIDDM patients | | Birkeland, 1994 | glipizide | glyburide | NIDDM patients |
|
| Glipizide | diabetes type 2, in all type of patients | vs placebo | - | - | - | - | - | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| All cause death | no data | | stroke (fatal and non fatal) | no data | | myocardial infarction (fatal and non fatal) | no data | | microvascular events | no data | | macrovascular or microvascular events | no data | | Peripheral vascular events | no data | | Diabetes-related death | no data | | Any diabetes-related outcomes | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Simonson, 1997 | once-daily doses of 5, 20, 40, or 60 mg glipizide GITS | placebo | NIDDM patients | | Testa, 1998 | 5 to 20 mg of glipizide gastrointestinal therapeutic system (GITS) | placebo | patients with type 2 diabetes mellitus |
|
| Glipizide | diabetes type 2, in all type of patients | vs placebo (add on MET) | - | - | - | - | - | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| All cause death | no data | | stroke (fatal and non fatal) | no data | | myocardial infarction (fatal and non fatal) | no data | | microvascular events | no data | | macrovascular or microvascular events | no data | | Peripheral vascular events | no data | | Diabetes-related death | no data | | Any diabetes-related outcomes | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Feinglos, 2005 | 2.5 mg glipizide GITS | placebo | type 2 diabetes inadequately controlled (A1c 7-8.5%) on metformin (> or =1000 mg/day for > or =3 months) |
|
| Glipizide | diabetes type 2, in all type of patients | vs sitagliptin (add on MET) | - | - | - | - | - | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| All cause death | no data | | stroke (fatal and non fatal) | no data | | myocardial infarction (fatal and non fatal) | no data | | microvascular events | no data | | macrovascular or microvascular events | no data | | Peripheral vascular events | no data | | Diabetes-related death | no data | | Any diabetes-related outcomes | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Nauck, 2007 | glipizide | sitagliptin | |
|
| Glyburide | diabetes type 2, in all type of patients | vs c (add on MET) | - | - | - | - | - | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| All cause death | no data | | stroke (fatal and non fatal) | no data | | myocardial infarction (fatal and non fatal) | no data | | microvascular events | no data | | macrovascular or microvascular events | no data | | Peripheral vascular events | no data | | Diabetes-related death | no data | | Any diabetes-related outcomes | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Hermann, 1991 | metformin + glibenclamide | metformin | patients with non-insulin-dependent diabetes mellitus | | DeFronzo, 1995 | metformin and glyburide | metformin | patients with non-insulin-dependent diabetes mellitus | | Erle, 1999 | low-dose glyburide plus metformin | high-dose glyburide alone | |
|
| Glyburide | diabetes type 2, in all type of patients | vs control (add on MET) | - | - | - | - | - | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| All cause death | no data | | stroke (fatal and non fatal) | no data | | myocardial infarction (fatal and non fatal) | no data | | microvascular events | no data | | macrovascular or microvascular events | no data | | Peripheral vascular events | no data | | Diabetes-related death | no data | | Any diabetes-related outcomes | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Marre (ass), 2002 | metformin-glibenclamide 500 mg/2.5 mg or metformin-glibenclamide 500 mg/5 mg, titrated with the intention to achieve fasting plasma glucose (FPG) < or = 7 mmol/l | metformin 500 mg, | patients with Type 2 diabetes mellitus inadequately controlled by metformin monotherapy | | Blonde, 2002 | glyburide/metformin 2.5 mg/500 mg (n = 160); or glyburide/metformin 5 mg/500 mg (n = 162) | metformin 500 mg | patients with inadequate glycaemic control on at least half-maximal dose of sulphonylurea | | Tosi, 2003 | metformin 400 to 2,400 mg/d + glibenclamide 2.5 to 15 mg/d | metformin (500 to 3,000 mg/d), | | | Garber, 2003 | glyburide/metformin | metformin | patients with type 2 diabetes who had inadequate glycemic control [glycosylated hemoglobin A(1C) (A1C), >7% and <12%) with diet and exercise alone |
|
| Glyburide | diabetes type 2, in all type of patients | vs placebo | - | - | - | - | - | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| All cause death | no data | | stroke (fatal and non fatal) | no data | | myocardial infarction (fatal and non fatal) | no data | | microvascular events | no data | | macrovascular or microvascular events | no data | | Peripheral vascular events | no data | | Diabetes-related death | no data | | Any diabetes-related outcomes | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Garber, 2002 | glyburide 2.5 mg | placebo | patients with type 2 diabetes who had failed diet and exercise | | Vray, 1995 | glibenclamide (2.5 mg X 3/d) | placebo | type 2 diabetic outpatients, 40-70 years of age, treated by diet alone or oral anti-diabetic drugs |
|
| Glyburide | diabetes type 2, in all type of patients | vs rosiglitazone (add on MET) | - | - | - | - | - | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| All cause death | no data | | stroke (fatal and non fatal) | no data | | myocardial infarction (fatal and non fatal) | no data | | microvascular events | no data | | macrovascular or microvascular events | no data | | Peripheral vascular events | no data | | Diabetes-related death | no data | | Any diabetes-related outcomes | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Garber, 2006 | metformin-glibenclamide 500/2.5 mg tablets (initial daily dose 1000/5 mg) | metformin 500 mg plus rosiglitazone 4 mg (initial daily dose 1000-2000 mg + 4 mg, depending on previous treatment) | patients with type 2 diabetes inadequately controlled on metformin monotherapy |
|
